Medicinova(JP:4875)
¥234.00+4.00 (+1.74%)
JP:4875
Medicinova stock drug pipeline
¥234.00
At close:+4.00 (+1.74%)
Medicinova (4875) Drug Pipeline
0 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Mn-001 | Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease | Phase II | Recruiting | MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia | Jun 28, 2022 | ― |
| Ibudilast | Pneumonia, Viral | Phase II | Completed | Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS | Jun 09, 2020 | ― |
| Mn-166 | Healthy Volunteers | Phase I | Completed | Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers | Aug 06, 2019 | ― |
| Mn-166 | Amyotrophic Lateral Sclerosis | phase2AndPhase3 | Active Not Recruiting | Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | Aug 06, 2019 | ― |
| Temozolomide, Mn-166 | Glioblastoma, Gbm, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma | phase1AndPhase2 | Completed | Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma | Dec 17, 2018 | ― |
| Mn-166 | Healthy Volunteers | Phase I | Completed | Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers | Apr 18, 2018 | ― |
| Ibudilast | Amyotrophic Lateral Sclerosis | phase1AndPhase2 | Completed | A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) | Mar 09, 2016 | ― |
| Mn-001 | Hypercholesterolemia, Hypertriglyceridemia, Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease | Phase II | Completed | Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects | Feb 05, 2016 | ― |
| Mn-001 | Idiopathic Pulmonary Fibrosis, Ipf | Phase II | Completed | Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis | Jul 14, 2015 | ― |
| Mn-166, Riluzole | Amyotrophic Lateral Sclerosis | Phase II | Completed | Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Sep 04, 2014 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Mn-001 | Phase II | Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease | Recruiting | MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia | Jun 28, 2022 | ― |
| Ibudilast | Phase II | Pneumonia, Viral | Completed | Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS | Jun 09, 2020 | ― |
| Mn-166 | Phase I | Healthy Volunteers | Completed | Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers | Aug 06, 2019 | ― |
| Mn-166 | phase2AndPhase3 | Amyotrophic Lateral Sclerosis | Active Not Recruiting | Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | Aug 06, 2019 | ― |
| Temozolomide, Mn-166 | phase1AndPhase2 | Glioblastoma, Gbm, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma | Completed | Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma | Dec 17, 2018 | ― |
| Mn-166 | Phase I | Healthy Volunteers | Completed | Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers | Apr 18, 2018 | ― |
| Ibudilast | phase1AndPhase2 | Amyotrophic Lateral Sclerosis | Completed | A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) | Mar 09, 2016 | ― |
| Mn-001 | Phase II | Hypercholesterolemia, Hypertriglyceridemia, Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease | Completed | Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects | Feb 05, 2016 | ― |
| Mn-001 | Phase II | Idiopathic Pulmonary Fibrosis, Ipf | Completed | Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis | Jul 14, 2015 | ― |
| Mn-166, Riluzole | Phase II | Amyotrophic Lateral Sclerosis | Completed | Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Sep 04, 2014 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Medicinova (JP:4875) have in its pipeline
Medicinova JP:4875 is currently developing the following drugs: Mn-001, Ibudilast, Mn-166, Temozolomide, Mn-166, Mn-166, Riluzole. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

